A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Q4 2024 Earnings Call Transcript March 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

In parallel, we continue to build strong differentiating evidence for sotagliflozin, an SGLT1/2 inhibitor, and we are continuing to enroll a Phase 3 clinical trial in support of a potential broad ...

Reports Q4 revenue $$26.55M, consensus $6.48M.Cash and Investments: As of December 31 , Lexicon (LXRX) had $238M in cash and short-term ...

Role of SGLT2 and SGLT1 in glucose re-absorption within the proximal renal ... approved class of hypoglycemic drugs known as SGLT2 inhibitors (SGLT2i) to treat diabetes mellitus (DM) in cats. We ...

The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...

Neither of the selective SGLT2 inhibitors have yet been shown to reduce MI and stroke events. Sotagliflozin, however, inhibits SGLT2 as well as gastrointestinal SGLT1; the latter effect, the study ...

Unlike other SGLT2 inhibitors, it uniquely blocks both SGLT1 and SGLT2, offering distinct cardiovascular benefits. Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients ...